JIN-TOWN WANGWANG T.-H.LIN J.-T.Lee, Cha-ZeCha-ZeLeeJIN-CHUAN SHEUDING-SHINN CHEN2021-02-022021-02-0219950815-9319https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029089762&doi=10.1111%2fj.1440-1746.1995.tb01599.x&partnerID=40&md5=45160f0b251692d022c3933a485a4f24https://scholars.lib.ntu.edu.tw/handle/123456789/545864A national screening programme for antibody to hepatitis C virus (HCV) in blood donors in Taiwan began in July 1992 using a second?generation immunoassay. To study the impact of this screening on post?transfusion hepatitis in Taiwan, a prospective study on post?transfusion hepatitis, that was started in 1987, was continued. As of June 1994, 245 patients who received a blood transfusion after July 1992 had completed a follow?up period for more than 6 months post?transfusion. Of them, seven (2.8%) recipients developed acute post?transfusion hepatitis. The hepatitis in six cases could not be attributed to infection by hepatitis A, B, C, D, E viruses or cytomegalovirus (CMV) or Epstein?Barr virus (EBV). The remaining patient seroconverted to both IgG and IgM anti?CMV. All seven patients recovered in 6 months without development of chronicity, and the mean peak alanine aminotransferase level was lower compared with that of the cases before anti?HCV screening (i.e. pre?July 1992). These results indicate that the current anti?HCV screening has effectively interrupted HCV transmission through blood transfusion in Taiwan. Copyright ? 1995, Wiley Blackwell. All rights reserved[SDGs]SDG3hepatitis C antibody; adult; aged; article; blood transfusion; donor; female; hepatitis; hepatitis C; human; major clinical study; male; priority journal; screening; seroconversion; Taiwan; virus transmissionjournal article10.1111/j.1440-1746.1995.tb01599.x2-s2.0-0029089762